ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,00%
Dow Jones
38 686,32
1,51%
DAX
0,00
0,00%
Brent Oil
80,875
0,09%
Bitcoin
69 154,51
2,08%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Novartis AG (NVS)

  7. Novartis AG (NVS) Actualités

NVS

Novartis (NVS)

Novartis AG
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:NVS
DateHeureSourceTitreSymboleSociété
25/05/202412h15PR Newswire (US)Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolioNYSE:NVSNovartis AG
25/05/202412h00PR Newswire (US)Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placeboNYSE:NVSNovartis AG
24/05/202422h31Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
22/05/202418h42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:NVSNovartis AG
07/05/202413h00GlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNYSE:NVSNovartis AG
23/04/202413h25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:NVSNovartis AG
15/04/202420h00PR Newswire (US)New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)NYSE:NVSNovartis AG
11/04/202413h00GlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNYSE:NVSNovartis AG
10/04/202413h13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:NVSNovartis AG
06/04/202422h16PR Newswire (US)New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world settingNYSE:NVSNovartis AG
15/02/202422h15Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNYSE:NVSNovartis AG
06/02/202422h52Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNYSE:NVSNovartis AG
06/02/202412h14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNYSE:NVSNovartis AG
02/02/202420h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:NVSNovartis AG
31/01/202413h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:NVSNovartis AG
31/01/202413h42Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NYSE:NVSNovartis AG
31/01/202413h38Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NYSE:NVSNovartis AG
31/01/202412h28IH Market NewsWalmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and MoreNYSE:NVSNovartis AG
22/01/202407h59Dow Jones NewsSandoz to Acquire Cimerli Business from Coherus for $170 MillionNYSE:NVSNovartis AG
12/01/202412h10IH Market NewsWall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and MoreNYSE:NVSNovartis AG
11/01/202419h02Dow Jones NewsCytokinetics Shares Slide as Novartis Reportedly Shies Away From DealNYSE:NVSNovartis AG
08/01/202419h43Dow Jones NewsCytokinetics Shares Jump 16% After WSJ Report of Novartis DealNYSE:NVSNovartis AG
08/01/202416h41Dow Jones NewsNovartis on Track for Record High Close -- Data TalkNYSE:NVSNovartis AG
08/01/202408h01Dow Jones NewsNovartis's Scemblix Drug Meets Main Goals in Late-Stage Leukemia TrialNYSE:NVSNovartis AG
05/01/202416h15Dow Jones NewsNovartis to Make Pluvicto Radioligand Therapy at Indianapolis PlantNYSE:NVSNovartis AG
02/01/202413h46Dow Jones NewsVoyager Therapeutics Shares Leap Premarket on Novartis CollaborationNYSE:NVSNovartis AG
11/12/202308h02Dow Jones NewsNovartis Drug Meets Primary Goal in Late-Stage Study for Kidney DiseaseNYSE:NVSNovartis AG
11/12/202301h39PR Newswire (US)Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)NYSE:NVSNovartis AG
06/12/202311h14Dow Jones NewsMerck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage TrialsNYSE:NVSNovartis AG
06/12/202306h18PR Newswire (US)Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHNYSE:NVSNovartis AG
 Showing the most relevant articles for your search:NYSE:NVS

Dernières Valeurs Consultées

GATE
SHFTUSDT
Shyft [ Wrapped ]
EU
SPLR
Leverage Shares 1x Short...
NASDAQ
RTTR
Ritter Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés